Results Highlights for Interim Results ended 30 June 2026

Revenue reached RMB1,006.5 million, increasing by 21.0% YoY

Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY

Gross profit margin was 34.0%

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings Group ("the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB1,006.5 million and gross profit of RMB341.7 million, representing a gross margin of 34.0%. Overall, the Group's total revenue grew by approximately 21.0% year-on-year, primarily driven by the significant contribution from Langhua Pharmaceutical's CDMO business, under which one peptide project has entered the commercial production phase and the other small-molecule project has reached the PPQ phase. In addition, in the first half of 2026, the Group recorded a net profit of RMB100.9 million and an adjusted non-IFRS net profit of RMB128.3 million, both representing a decline compared with the corresponding period of last year. This was mainly attributable to a decrease in investment income contributions during the Reporting Period, unfavorable foreign exchange movements and increased R&D expenses associated with new business development.

CRO Revenue Growth Set for Recovery, with AI-Driven Drug R&D Leading a New Paradigm in Drug Discovery

In the first half of 2026, the Group's CRO revenue amounted to RMB405.1 million; adjusted gross profit for the corresponding period reached RMB173.7 million. Backed by a strong order backlog and the ongoing expansion of AI and other new technology platforms, the Company is expected to maintain a full-year growth rate in 2026 at or above its current level.

The Group's cumulative number of CRO clients increased to 1,984, including the top 10 global pharmaceutical companies, with the top 10 clients accounting for 26.6% of CRO revenue.

As of June 30, 2026, the Company had cumulatively delivered over 108,163 protein structures to clients, of which approximately 9,278 were newly delivered in the first half of 2026. Cumulatively, over 2,557 independent drug targets have been studied, with 212 newly delivered in the first half of 2026. The number of delivered independent drug targets grew markedly, driven by the rapid advancement of AI-powered drug discovery and the resulting surge in wet-lab demand. The Company continues to lead the industry globally in protein structure determination. New modality offerings, including peptides, antibodies, XDCs, and PROTACs/molecular glues, accounted for approximately 17.7% of total CRO revenue, representing a year-on-year increase of nearly 10.7%.

As of June 30, 2026, CADD/AIDD had cumulatively participated in 228 projects, with 92 cumulative clients having procured CADD/AIDD services. Revenue contribution from AI-empowered projects accounted for approximately 14.0% of total CRO revenue. A deep collaboration with a global industry leader advanced our AI-driven "dry-wet closed-loop" model, laying a foundation for future MNC partnerships. The CADD/AIDD team launched the MARS multimodal integrated algorithm platform, leveraging Pep2MARS to establish a strong competitive advantage in designing peptides, cyclic peptides, and complex macrocycles. Through the comprehensive upgrade of its three underlying modules, V-Scepter, V-Orb, and V-Mantle, the platform will significantly boost drug design efficiency and accelerate practical applications.

CDMO Commercial Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves Profitability

During the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment and optimization of its client portfolio, the CMC business has continuously improved project delivery rates, and has successfully achieved a turnaround from loss to profitability.

For the first half of 2026, Langhua Pharmaceutical recorded total revenue of RMB601.4 million, representing a year-on-year increase of approximately 47.0%. Adjusted gross profit totaled RMB175.1 million, up approximately 12.9% year-on-year. The revenue growth was primarily driven by two new CDMO commercialization projects. A peptide project has entered the commercial stockpiling stage, and a small-molecule project is currently at the PPQ production stage. Meanwhile, the API and the intermediates and formulations business are expected to gradually recover in the second half of the year. As of June 30, 2026, Langhua Pharmaceutical had served a cumulative total of 920 clients, with a 100.0% retention rate among its top ten customers. The current total production capacity stands at 860 cubic meters, which is sufficient to support the actual commercial production of new commercialized products over the next two years. In addition, an additional 400 cubic meters of capacity is being constructed to cater to the future volume growth of new molecule commercial production.

In 2025, the Group established a new PPO (Peptides, Proteins and Oligo Nucleotides) business unit. It is also one of the Group's key strategic focuses for future development. The unit has already completed peptide CMC-related capabilities and team assembly. During the Reporting Period, the unit delivered 21 peptide projects accumulatively, with 19 projects currently in progress. Going forward, the PPO business unit will continue to strengthen its technological capabilities in peptides, conjugated drugs, and small nucleic acids.

Exit Proceeds to Be Deployed Towards Incubation of New Projects

During the Reporting Period, the Group realized aggregate cash proceeds of approximately RMB218.4 million from successful exits of several incubation portfolio companies over the past year and in the first half of this year. The Company plans to deploy a portion of such proceeds towards incubating new projects, leveraging its existing AI+SBDD dry-wet experimental platform. As of June 30, 2026, the Group had invested in and incubated a cumulative total of 93 start-up companies, with a cumulative total of nearly 232 pipelines under development, of which 188 are in the preclinical stage and 44 have advanced into the clinical stage. To date, the Group has achieved full or partial exits from 19 incubated companies.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-rd-cdmo-commercial-manufacturing-accelerates-revenue-growth-302861178.html

Im Streit um die Behandlung sogenannter Heavy User im Mobilfunk hat das nordrhein-westfälische Oberverwaltungsgericht (OVG) die Bundesnetzagentur vorläufig in die Schranken gewiesen. Die Bonner Aufsichtsbehörde hatte einem bundesweit tätigen Mobilfunkanbieter untersagt, Kunden mit unbegrenztem oder sehr großem Datenvolumen bei überlasteten Funkzellen mit geringerer Priorität zu bedienen. Diese Form der sogenannten Depriorisierung darf nach der einstweiligen OVG-Entscheidung vorerst weiter angewendet werden. Der Beschluss im Eilverfahren ist nicht anfechtbar.

Nach Auffassung des 13. Senats ist derzeit offen, ob die entsprechende Vertragsklausel des Anbieters mit europäischem Recht vereinbar ist. Im Kern geht es um die Frage, ob eine nachrangige Behandlung von Vielnutzern eine nicht gerechtfertigte Ungleichbehandlung von Kunden darstellt. Bevor in der Hauptsache entschieden wird, will das OVG Münster den Europäischen Gerichtshof (EuGH) um eine Vorabentscheidung bitten. Damit wird der Konflikt um Datenpriorisierung und Netzmanagement auf die europäische Ebene verlagert.

Gegenstand des Verfahrens ist insbesondere, ob der Datentransport datenintensiver Anwendungen wie hochauflösendem Videostreaming während einer Netzüberlastung eingeschränkt oder verlangsamt werden darf. Der betroffene Mobilfunkanbieter sieht dies in seinen Allgemeinen Geschäftsbedingungen vor, um Kapazitäten in ausgelasteten Funkzellen zu steuern. Die Bundesnetzagentur hatte angeordnet, dass diese Klausel nicht umgesetzt werden darf und damit faktisch einen Riegel vor entsprechende Maßnahmen gegen Heavy User geschoben.

In der Vorinstanz hatte sich die Bundesnetzagentur noch durchgesetzt: Das Verwaltungsgericht Köln hatte die Position der Behörde bestätigt. Das OVG änderte diese Entscheidung nun (Az. 13 B 1232/25) und gab dem Anbieter im Eilverfahren Recht. Mit der geplanten Vorlage an den EuGH dürfte der Fall Signalwirkung für die Auslegung europäischer Vorgaben zur Gleichbehandlung von Internetverkehr und zu den Spielräumen der Netzbetreiber beim Umgang mit stark belasteten Mobilfunkzellen entfalten.